HiJAKing T-ALL.
In the current issue of Blood, Degryse and coauthors report the transforming potential of a series of JAK3 mutations identified in primary T-cell acute lymphoblastic leukemia (T-ALL) samples and pave the way toward multitargeted JAK1 and JAK3 therapy in T-ALL.